Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.First-line poly(ADP-ribose) polymerase inhibitor maintenance therapy is rising for ovarian cancer. Progression timing after first-line olaparib maintenance impacts subsequent therapy efficacy, with longer duration when progression occurs after treatment completion.
Area Of Science
- Oncology
- Gynecologic Oncology
- Clinical Pharmacology
Background
- Increasing use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy in advanced ovarian cancer.
- Need to understand first subsequent therapy (FST) efficacy after disease progression in the first-line setting.
- Evaluation of FST efficacy in patients from the PAOLA-1/ENGOT-ov25 trial who received first-line olaparib maintenance.
Purpose Of The Study
- To evaluate the efficacy of FST in advanced ovarian cancer patients who received first-line olaparib maintenance.
- To assess the impact of disease progression timing (during vs. after first-line olaparib maintenance) on FST efficacy.
- To identify prognostic factors for subsequent chemotherapy efficacy in the olaparib plus bevacizumab arm.
Main Methods
- Post hoc analysis of the PAOLA-1/ENGOT-ov25 trial.
- Assessment of time from FST to second subsequent therapy (SST).
- Multivariate Cox model analysis in the olaparib plus bevacizumab arm to identify prognostic factors.
Main Results
- Of 806 patients, 544 (67.5%) progressed and received subsequent chemotherapy.
- Median time from FST to SST was shorter (6.1 months) for progression during first-line olaparib maintenance versus after (11.4 months).
- Progression after first-line olaparib maintenance was an independent prognostic factor for longer time from FST to SST (HR 0.65, P=0.0011).
Conclusions
- Timing of disease progression relative to first-line olaparib maintenance influences subsequent platinum-based chemotherapy efficacy.
- Longer time from FST to SST observed when progression occurs after first-line olaparib maintenance compared to during.
- Efficacy of subsequent therapies, including PARP inhibitor rechallenge, is dependent on progression timing.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...